Royalty Pharma plc-A 2026年季度报告

FORM 13F COVER PAGE 12-31-2025 Report for the Calendar Year or Quarter Ended: Amendment Number:is a restatement.adds new holdings entries. Check here if Amendment This Amendment (Check only one.): Institutional Investment Manager Filing this Report: Royalty Pharma plc110 EAST 59th StreetNew York,NY10022028-26788 Name:Address: Form 13F File Number:CRD Number (if applicable):SEC File Number (if applicable): The institutional investment manager filing this report and the person by whom it is signed hereby represent that theperson signing the report is authorized to submit it, that all information contained herein is true, correct andcomplete, and that it is understood that all required items, statements, schedules, lists, and tables, are consideredintegral parts of this form. Person Signing this Report on Behalf of Reporting Manager:Name:Jason Mehar Title:SVP, Investments & Deputy General CounselPhone:212-883-2271 Signature, Place, and Date of Signing: /s/ Jason Mehar Report Type (Check only one.): 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)X13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reportingmanager(s).)13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this reportand a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager:[If there are no entries in this list, omit this section.] NameForm 13F File No.CRD No. (ifapplicable)SEC File No. (ifapplicable)CIKRoyalty Pharma Sub-Manager, LLC